CC
DYN icon

Commodore Capital’s Dyne Therapeutics DYN Stock Holding History

Commodore Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-900,000
Closed -$12M – 41
2023
Q4 		$12M Buy
+900,000
New +$8.79M 1.05% 26
2022
Q2 		– Sell
-305,125
Closed -$2.94M – 26
2022
Q1 		$2.94M Hold
305,125
– – 0.66% 24
2021
Q4 		$3.63M Hold
305,125
– – 0.84% 20
2021
Q3 		$4.96M Hold
305,125
– – 1.31% 23
2021
Q2 		$6.42M Sell
305,125
-124,987
-29% -$2.35M 2.24% 19
2021
Q1 		$6.68M Buy
+430,112
New +$8.32M 2.66% 18

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital's DYN Position: Q1 2024 in Review

Commodore Capital sold out of Dyne Therapeutics (DYN) in Q1 2024, closing a stake of 900,000 shares — an estimated $12M sold.

Commodore Capital first reported a position in DYN in Q1 2021 and held it in 6 quarters. The position peaked at $12M in Q4 2023. 169 funds tracked by Wall St. Rank hold DYN as of Q1 2024.

  • Commodore Capital reported no remaining Dyne Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Commodore Capital sold 900,000 Dyne Therapeutics shares in Q1 2024, an estimated $12M.
  • Commodore Capital first reported a position in Dyne Therapeutics in Q1 2021 and held it in 6 quarters.
  • Commodore Capital's Dyne Therapeutics position peaked at $12M in Q4 2023.
  • 169 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2024.

Based on Commodore Capital's 13F filing for Q1 2024, filed 15 May 2024.